Search results
Results From The WOW.Com Content Network
2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 ... Sanofi-Aventis: Diabetes mellitus type 1 and 2: Apr-2000: 2011-Dec 10: Neulasta:
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the time ...
CEO, Sanofi. Term. September 2019-. Predecessor. Olivier Brandicourt. Children. 3. Paul Hudson (born 14 October 1967) [ 2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [ 3]
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
The news comes months after Sanofi announced it was reviewing "separation scenarios" for the unit in a bid to focus on its core innovative drugs business. Sanofi's consumer healthcare spin-off ...
July 2, 2024 at 10:05 AM. (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had warned a website called ozempen.com against unlawfully selling versions of Novo Nordisk's weight ...
Curia (formerly AMRI or Albany Molecular Research Inc. [2]) is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its ...
Sales of the company's main product, Provenge, increased in the first half of 2012 compared to last year, but not enough to avoid further cost reductions. This second round of layoffs provides ...